Resources
15 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 3/25/2021 (updated 4/5/2024)
Effective Harm Reduction Strategies for People Who Actively Use Opioids and/or Psychostimulants
Participants will learn evidenced-based harm reduction strategies to keep people who use opioids and psychostimulants alive with reduced disease burden. Presenters will discuss methods of engaging people who actively use opioids and/or psychostimulants, harm reduction interventions, overdose prevention and response, overamping prevention and response, and linkages to care.
Posted 3/6/2021 (updated 4/5/2024)
HepVu released new interactive maps visualizing U.S. county-level Hepatitis C-related mortality, illustrating how factors such as age and geographic region affect health outcomes. Published in Hepatology, the data demonstrate that Hepatitis C-related mortality has been decreasing across the U.S. since 2013
Posted 11/11/2021 (updated 4/3/2024)
In these challenging times, some of our most important problems are intractable. Examples include health inequity, hybrid workplaces, systemic racism, maternal and child health, and a trained and available workforce. In this session, presenters introduced tools to help you lead, even when solutions are beyond your control. They applied those tools to help you recruit and sustain a workforce for tomorrow.
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/4/2021 (updated 4/2/2024)
Posted 7/7/2021 (updated 4/2/2024)
In 2015, 33,091 persons in the United States died from an opioid-related drug overdose.The epidemic of opioid overdose deaths has led to expanding the use of naloxone in community settings by non–medically trained bystanders who are often people who use drugs (PWUD). Since 2013, illicitly manufactured fentanyl (IMF), fentanyl analogs, and other synthetic opioids have played an increasing role in overdose deaths in the United States. Illicitly manufactured fentanyl (IMF) prevalence has increased. However, there is uncertainty about naloxone dose(s) used by nonmedical bystanders to reverse opioid overdoses in the context of increasing IMF.
Posted 6/30/2021 (updated 4/2/2024)
In this context, the overarching aim of this document is to inform and encourage governments, policy–makers, and other partners to take the necessary actions to implement evidence-based prevention strategies and treatment services for substance use disorders in order to provide everybody, girls as well as boys, and women as well as men, with the skills and opportunities to prevent the initiation of unhealthy behaviours and, in case of individuals who use drugs and suffer from drug use disorders, with the optimal support for improving their life circumstances.
Posted 6/2/2020 (updated 3/28/2024)
We know from RCORP grantees, first responders, hospitals, people who use drugs, the media and other allies that many communities are seeing spikes in overdose (OD) events and deaths since the onset of COVID-19. Sometimes these deaths come at alarming levels because of stretched public health infrastructure and the time it takes to turn around data. The webinar took place on May 26, 2020.